On November 11, 2022 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, reported that it will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 (Press release, Cue Biopharma, NOV 11, 2020, View Source [SID1234608290]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cue Biopharma will provide an overview highlighting the Immuno-STAT (Selective Targeting and Alteration of T cells) platform, its expanding pipeline and anticipated milestones. The presentations will also include an update on the Company’s ongoing Phase 1 monotherapy dose escalation trial of CUE-101 including details pertaining to patients from cohorts 4, 5, and 6 being treated for HPV16-driven recurrent/metastatic head and neck cancer.

Additional conference details can be found below:

Stifel Virtual Healthcare Conference 2020
Date and Time: November 18, 2020 at 9:20 a.m. EST
Webcast Link: View Source
A live and archived webcast of the presentation will be available in the Investors section of the Company’s website at www.cuebiopharma.com. .

Jefferies Virtual London Healthcare Conference
Date and Time: November 19, 2020 at 9:05 a.m. EST
Webcast link: View Source
A live and archived webcast of the presentation will be available in the Investors section of the Company’s website at www.cuebiopharma.com. .